Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 5/20 | 0.51 |
| ▸ | DRD3 | P35462 | 5/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5051400 | 1.00 | PLAU (0.55) | PLAUDRD2DRD3GRIN1GRIN2B | |
| SCHEMBL29668981 | 1.00 | PLAU (0.55) | PLAUDRD2DRD3GRIN1GRIN2B | |
| SCHEMBL3310824 | 0.85 | PLAU (0.55) | PLAUDRD2DRD3GRIN1GRIN2B | |
| SCHEMBL30279709 | 0.85 | PLAU (0.55) | PLAUDRD2DRD3GRIN1GRIN2B | |
| SCHEMBL369136 | 0.82 | PLAU (0.41) | PLAUDRD2DRD3 | |
| Hydrochloric Acid SCHEMBL27034209 | 0.81 | DRD2 (0.40) | PLAUDRD2DRD3 | |
| SCHEMBL2463278 | 0.79 | CYP2D6 (0.44) | PLAUDRD2DRD3OPRK1 | |
| SCHEMBL8267166 | 0.78 | DRD2 (0.55) | DRD2DRD3GRIN1GRIN2BHSD17B10 | |
| SCHEMBL14819902 | 0.78 | DRD2 (0.51) | DRD2DRD3GRIN1GRIN2BOPRK1 | |
| SCHEMBL22791667 | 0.78 | DRD2 (0.51) | DRD2DRD3GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060757-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED INC. (CA) | 2007-03-15 | — | — | US | claimed |
| CN-1608052-A | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED INC (CA) | 2005-04-20 | — | — | CN | claimed |
| US-20050080267-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED, INC. (CA) | 2005-04-14 | — | — | US | claimed |
| EP-1487795-A4 | SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS | ANORMED INC (CA) | 2005-02-09 | — | — | EP | claimed |
| EP-1487795-A2 | SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS | ANORMED INC. (CA) | 2004-12-22 | — | — | EP | claimed |
| US-20030114679-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED CORPORATION (CA) | 2003-06-19 | — | — | US | claimed |
| WO-2003022785-A2 | SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS | ANORMED INC. (CA) | 2003-03-20 | — | — | WO | claimed |
| US-11992494-B2 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-05-28 | — | — | US | disclosed |
| EP-3558310-B1 | HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20230190763-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-06-22 | — | — | US | disclosed |
| CN-110325531-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2022-05-27 | — | — | CN | disclosed |
| US-11319298-B2 | Heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME CORP. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-11-16 | — | — | US | disclosed |
| US-20060111413-A1 | Antidiabetic agents, anticancer, non-cardiac ischemia, infection, hypertension, obesity and dislipidemia; 3-(5-chloroindole-2-carbonylamino)-2-hydroxy-1,2,3,4-tetrahydronaphthalene | BRISTOL-MYERS SQUIBB COMPANY | 2006-05-25 | — | — | US | disclosed |
| US-20050080267-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED, INC. (CA) | 2005-04-14 | — | — | US | disclosed |
| EP-1487795-A4 | SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS | ANORMED INC (CA) | 2005-02-09 | — | — | EP | disclosed |
| EP-1487795-A2 | SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS | ANORMED INC. (CA) | 2004-12-22 | — | — | EP | disclosed |
| US-6825351-B2 | SELECTIVE HYDROGENATION OF AMINO-SUBSTITUTED FUSED BICYCLIC AROMATIC RING SYSTEM, PREPARATION OF RACEMIC AMINO SUBSTITUTED FUSED BICYCLIC RING SYSTEM VIA NITROSATION, ENZYMATIC RESOLUTION OF RACEMIC MIXTURE TO PRODUCE (R)- AND (S)-FORMS | ANORMED, INC. (CA) | 2004-11-30 | — | — | US | disclosed |
| US-20030114679-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | ANORMED CORPORATION (CA) | 2003-06-19 | — | — | US | disclosed |
| WO-2003022785-A2 | SYNTHESIS OF ENANTIOMERICALLY PURE AMINO-SUBSTITUTED FUSED BICYCLIC RINGS | ANORMED INC. (CA) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114679-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | CBR1, POR, CBR3 | PLAU 4255/4885DRD2 1371/4885DRD3 1315/4885 |
| US-11319298-B2 | Heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | CHRM4, CHRM2, CHRM5 | PLAU 4820/4885DRD2 74/4885DRD3 141/4885 |
| US-11992494-B2 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | PTAFR, PDGFRA, PDGFRB | PLAU 777/4885DRD2 2388/4885DRD3 2931/4885 |
| US-11174268-B2 | Benzenesulfonamide compouds and their use as therapeutic agents | KCND2, SCN1A, CACNA1D | PLAU 3413/4885DRD2 366/4885DRD3 468/4885 |
| US-20070060757-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | CBR1, POR, CBR3 | PLAU 4255/4885DRD2 1371/4885DRD3 1315/4885 |
| US-20050080267-A1 | Synthesis of enantiomerically pure amino-substituted fused bicyclic rings | CBR1, POR, CBR3 | PLAU 4255/4885DRD2 1371/4885DRD3 1315/4885 |
| US-20230190763-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | PTAFR, PDGFRA, PDGFRB | PLAU 777/4885DRD2 2388/4885DRD3 2931/4885 |
| US-20060111413-A1 | Antidiabetic agents, anticancer, non-cardiac ischemia, infection, hypertension, obesity and dislipidemia; 3-(5-chloroindole-2-carbonylamino)-2-hydroxy-1,2,3,4-tetrahydronaphthalene | PYGM, PON1, GYS1 | PLAU 1519/4885DRD2 4418/4885DRD3 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.